Cammie Edwards

Associate Director, Strategic Alliances
UCSF MMTI & Strategic Alliances

Cammie Edwards, PhD, Program and Alliance Management (ITA), provides a direct interface between UCSF teams and external collaboration partners. In that role, she works with both teams in establishing collaborative strategic plans, maintaining effective communication, promoting cross-functional activities, monitoring progress and developing risk mitigation strategies. Cammie joined UCSF as the Program Director for the Stephen and Nancy Grand Multiple Myeloma Translational Initiative (Grand MMTI) in 2011, where she provides strategic and operational oversight for the program. Prior to joining the Grand MMTI, Cammie worked for 10 years with DNA Bridges, Inc., a corporate development firm dedicated to helping life science companies advance their programs and products. In her role there, she assisted clients in raising funds (> $20 million in both private and federal funding), corporate positioning, business development and managing large contracts for clients. She worked successfully with both U.S. and international clients in a broad range of areas including cancer therapeutics, biologics, vaccines, biodefense and biomarker technologies. Cammie obtained her PhD from the University of California, Berkeley.

Check out the incredible speaker line-up to see who will be joining Cammie.

Download The Latest Agenda

Day 2

Sunday, April 10th, 2016

08:50 Chairperson’s Opening Address

09:00 PANEL: Adapting Your Risk Tolerance And Decision-Making Behaviors In Response To Today’s Scientific And Deal-Making Landscape

• Exploring how the rapid pace of scientific innovation is impacting our industry

o Identifying the best ways to keep up and not be overwhelmed by the pace of scientific innovation

• Examining how biotech financing options have shifted over the past year

• Determining how companies need to adapt their risk tolerance and decision-making behaviors as a response to rapid scientific innovation and changes to biotech financing alternatives

• How have transactions become riskier and how can you minimize this risk?

11:25 PANEL: Determining How Health Economics And Pricing Reimbursement Are Impacting Research Outcomes And Partnering Strategy

• Examining the current state of pricing reimbursement globally; what are the differences among Europe, the US, and other areas you work in?

• Explaining why health outcomes research so important to your potential partners; Will it continue to be a major driver?

• Debating whether health economics and research outcomes need to be incorporated into clinical trials no later than phase 2, and perhaps even in phase 1

• Establishing how health economic and research outcome data either drive value or cripple your opportunity for partnering

14:40 PANEL: Identifying Steps To A Successful Integration Management – From Contracting To Implementation

• Ensuring both the buy and the sell side get what they want in an acquisition or other integration deal, from contracting to implementation

• Exploring the people puzzle: determining the right people to keep and creating an effective process for letting others go

• Keeping discovery and development programs underway and on track

• Blending or preserving cultures and overcoming corporate integration hurdles

16:20 PANEL: Tackling Big Data And Real World Outcomes To Catalyze Further Growth In Your Pipeline

• Defining big data, real world outcomes, and real world data: which is the most actionable concept?

• With so much being logged and tracked electronically, how can real world data take processes and technology apart, then restructure them most efficiently?

• How can big data help us get more creative as to how we collaborate (even across industry verticals) to get to the actual solutions that patients and providers want

• Creating the right combination of people (prescribers and other healthcare institutions), processes, and technology to be successful using big data